Add 2 More Reports For 20% off

Report Overview

Brain tumors are a diverse group of cancers affecting the brain and spinal cord, with treatment typically beginning with surgery, followed by radiation and chemotherapy as first-line therapy. These tumors are the most common solid malignancy in children, accounting for approximately 25% of all pediatric cancer cases. They are the second-leading cause of tumor-related deaths among children. Despite the standard treatments, there is a significant unmet clinical need for more effective therapies due to the severe side effects and limited efficacy of current options. The growing focus on targeted therapies and immunotherapies is expected to drive significant advancements in the treatment pipeline.

  • Major companies involved in the pediatric brain tumors pipeline drugs market include NeonC Technologies, Inc., Pfizer, and others.
  • Leading drugs currently in the pipeline include Dabrafenib, NEO100, and others.
  • Advancements in targeted therapies, immunotherapies, and personalized medicine are anticipated to boost the pediatric brain tumor pipeline landscape.

Report Coverage

The Pediatric Brain Tumors Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into pediatric brain tumors therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for pediatric brain tumors. The pediatric brain tumors report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The pediatric brain tumors pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with pediatric brain tumors treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to pediatric brain tumors.

Pediatric Brain Tumors Drug Pipeline Outlook

Brain tumors are abnormal growths that develop in the brain or spinal cord, often resulting from genetic mutations, environmental factors, or a combination of both. These tumors can form in various parts of the brain, each affecting critical neurological functions, such as motor skills, vision, and cognitive abilities. Depending on their location and type, it can cause a range of symptoms, including headaches, nausea, and seizures, which may require immediate medical attention.

Treatment for pediatric brain tumors typically involves a combination of surgery, radiation therapy, and chemotherapy. Surgery is often the first step to remove as much of the tumor as possible, followed by radiation and chemotherapy to target any remaining cancerous cells. Recent advances have focused on personalized medicine, targeted therapies, and immunotherapy, offering new hope for improving treatment outcomes. Clinical trials are exploring these innovative treatments to minimize side effects and enhance survival rates, providing a more tailored approach for pediatric patients.

Pediatric Brain Tumors Epidemiology

Pediatric brain tumors, accounting for 25% of pediatric cancers and the second-leading cause of tumor-related deaths, present a significant clinical challenge. In the United States, approximately 208,620 adolescents and young adults live with primary brain or spinal cord tumors. In India, brain tumors comprise 8%-12% of childhood cancers, contrasting with 21% in Western countries, highlighting regional differences in incidence rates.

Pediatric Brain Tumors – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of pediatric brain tumors drug candidates based on several segmentations, including:

By Phase

  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products

By Drug Class

  • Small Molecules
  • Monoclonal Antibodies
  • Immunotherapies
  • Gene Therapies

By Route of Administration

  • Oral
  • Parenteral
  • Others

Pediatric Brain Tumors – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I covers a major share of the total pediatric brain tumors clinical trials.

Pediatric Brain Tumors – Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the pediatric brain tumors pipeline analysis include small molecules, monoclonal antibodies, immunotherapies, and gene therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for pediatric brain tumors.

Pediatric Brain Tumors Clinical Trials Therapeutic Assessment – Competitive Dynamics

The EMR pediatric brain tumors drug report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in pediatric brain tumors clinical trials:

  • Neonc Technologies, Inc.
  • Pfizer
  • Novartis Pharmaceuticals
  • Carthera, Photonamic GmbH & Co.KG
  • InSightec
  • Cellectar Biosciences, Inc.
  • Actuate Therapeutics Inc.
  • Eli Lilly and Company

Pediatric Brain Tumors Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for pediatric brain tumors. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of pediatric brain tumors drug candidates.

Drug: Dabrafenib

The Pediatric Long-Term Follow-up and Rollover Study, sponsored by Novartis Pharmaceuticals, aims to evaluate the long-term effects of dabrafenib and/or trametinib in pediatric patients. This Phase 4 study is expected to be completed by May 29, 2026, with around 166 participants. The objective is to assess the ongoing impact of these treatments on conditions like diffuse astrocytoma and oligodendroglioma.

Drug: Palbociclib

The Phase I/II study sponsored by Pfizer aims to evaluate the safety and maximum tolerable dose of p...

Drug: NEO100

The objective of the ongoing Phase 1b study sponsored by Neonc Technologies, Inc. is to evaluate the...

*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*

Reasons To Buy This Report

The Pediatric Brain Tumors Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for pediatric brain tumors. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into pediatric brain tumors collaborations, regulatory environments, and potential growth opportunities.

Key Questions Answered in the Pediatric Brain Tumors – Pipeline Insight Report

  • Which companies/institutions are leading the pediatric brain tumors drug development?
  • What is the efficacy and safety profile of pediatric brain tumors pipeline drugs?
  • Which company is leading the pediatric brain tumors pipeline development activities?
  • What is the current pediatric brain tumors commercial assessment?
  • What are the opportunities and challenges present in the pediatric brain tumors drug pipeline landscape?
  • What is the efficacy and safety profile of pediatric brain tumors pipeline drugs?
  • Which company is conducting major trials for pediatric brain tumors drugs?
  • Which companies/institutions are involved in pediatric brain tumors collaborations aimed at providing enhanced therapeutic alternatives for patients?
  • What are the geographies covered for clinical trials in pediatric brain tumors?

Related Reports

Global Brain Tumor Treatment Market

Glioma Market Report

Global Clinical Trials Market

*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*

Looking for specific insights?

Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!

Report Summary

Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.

Key Highlights of the Report

Please note that the figures mentioned in the description serve as estimates and may vary from the actual figures presented in the final report.

Scope of the Report

Details

Drug Pipeline by Clinical Trial Phase

  • Late-Stage Products (Phase III and Phase IV)
  • Mid-Stage Products (Phase II)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products

Route of Administration

  • Oral
  • Parenteral
  • Others

Drug Classes

  • Small Molecules
  • Monoclonal Antibodies
  • Immunotherapies
  • Gene Therapies

Leading Sponsors Covered

  • Neonc Technologies, Inc.
  • Pfizer
  • Novartis Pharmaceuticals
  • Carthera, Photonamic GmbH & Co.KG
  • InSightec
  • Cellectar Biosciences, Inc.
  • Actuate Therapeutics Inc.
  • Eli Lilly and Company

Geographies Covered

  • North America
  • Europe
  • Asia Pacific
  • Others

Mini Report

10 % Off

USD

1,999

1,799

Single User License

10 % Off

USD

3,099

2,789

Five User License

15 % Off

USD

4,599

3,909

Corporate License

15 % Off

USD

5,999

5,099

Mini Report

One User

USD 1,999

USD 1,799

tax inclusive*

  • Selected Segments
  • Printing Restrictions
  • Excel Spreadsheet Delivered via Email
  • Full Report
  • Periodic Updates
  • Post Sales Analysts Support
  • Unlimited Prints

Single User License

One User

USD 3,099

USD 2,789

tax inclusive*

  • All Segments
  • Printing Restrictions
  • PDF Delivered via Email
  • Custom Report Layout
  • Post Sales Analysts Support
  • Periodic Updates
  • Unlimited Prints

Five User License

Five User

USD 4,599

USD 3,909

tax inclusive*

  • All Segments
  • Five Prints Available
  • PDF Delivered via Email
  • Limited Free Customization
  • Post Sales Analyst Support
  • Custom Report Layout
  • Periodic Updates
  • Unlimited Prints

Corporate License

Unlimited Users

USD 5,999

USD 5,099

tax inclusive*

  • All Segments
  • Unlimited Prints Available
  • PDF & Excel Delivery via Email
  • Limited Free Customization
  • Post Sales Analysts Support
  • Discount On Next Update
  • Custom Report Layout

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Bundle Type

Flash Bundle

20% OFF Number of Reports: 3

Small Business Bundle

25% OFF Number of Reports: 5

Growth Bundle

30% OFF Number of Reports: 8

Enterprise Bundle

35% OFF Number of Reports: 10
Overview
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 80 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards
  • Life Time Access
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 100 Hours
  • Complimentary Free 1 Month Subscription to Trade Data Base
  • Complimentary One Month Subscription to Price Database (Chemicals only)
  • Complementary PPT Version of the Report
  • Complimentary License Upgrade
  • Complimentary Power BI Dashboards

*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*

Flash Bundle

Number of Reports: 3

20%

tax inclusive*

  • 3 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade
  • Free Analyst Hours

Small Business Bundle

Number of Reports: 5

25%

tax inclusive*

  • 5 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • Complimentary Excel Data Set
  • PPT Version of the Report
  • Power BI Dashboards
  • License Upgrade

Growth Bundle

Number of Reports: 8

30%

tax inclusive*

  • 8 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Free Analyst Hours - 80 Hours
  • Power BI Dashboards

Enterprise Bundle

Number of Reports: 10

35%

tax inclusive*

  • 10 Reports Included
  • Life Time Acess
  • Analyst Support Related to Report
  • PDF Version of the Report
  • Complimentary Excel Data Set
  • Free Analyst Hours - 50 Hours
  • Free 1 Month Subscription to Trade Data Base
  • 1 Month Subscription to Price Database (Chemicals only)
  • License Upgrade
  • Power BI Dashboards
  • Free Analyst Hours - 100 Hours

How To Order

Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.

Select License Type

Choose the right license for your needs and access rights.

Click on ‘Buy Now’

Add the report to your cart with one click and proceed to register.

Select Mode of Payment

Choose a payment option for a secure checkout. You will be redirected accordingly.

Strategic Solutions for Informed Decision-Making

Connect For More Information

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.

We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.

Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.

We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.

We’re here to help answer any questions about our products and services.

Contact us

Our Offices


Australia

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

India

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

Philippines

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.

+63-287-899-028, +63-967-048-3306

United Kingdom

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

United States

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

Vietnam

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124

30 North Gould Street, Sheridan, WY 82801

+1-415-325-5166

63 Fiona Drive, Tamworth, NSW

+61-448-061-727

C130 Sector 2 Noida, Uttar Pradesh 201301

+91-858-608-1494

40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.

+63-287-899-028, +63-967-048-3306

6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London

+44-753-713-2163

193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City

+84-865-399-124